Global Scleroderma Diagnostics and Therapeutics Market to reach nearly USD 4127.6 million by 2028

The global scleroderma diagnostics and therapeutics market was approximately USD 2232.5 million in 2021 and is anticipated to reach nearly USD 4127.6 million by 2028, with a compound annual growth rate (CAGR) of about 9.2 percent over the forecast period

Scleroderma is a group of medical conditions generally observed in women between the age group of 30 to 50 and involves hardening or tightening of skin or connecting tissues. It is an extremely rare medical disorder and symptoms may involve joint pain, exaggerated response to cold also known as Raynaud's disease, and heartburn. The initial body parts affected by the disease involve hands,  face, and fingers whereas skin thickening may involve areas like upper arms, forearms, chest, lower legs, thighs, and abdomen.

The disease is caused by overproduction and accumulation of collagen which is a fibrous protein that is essential in the making up of our connecting tissues. However, there are no concrete causes for the disease but apparently, the immunity system of an individual plays an extreme role in protecting from the disorder.

Covid-19 impacted the global scleroderma diagnostics and therapeutics market negatively at the beginning because of the priority given to Covid-19 patients; however, by the beginning of 2021, the global market slowly picked up the pace and is expected to grow during the forecast period.

Even though scleroderma is a rare disease, the reported cases have been rising significantly in the past few years. As reported by a study submitted by the British Society of Rheumatology in 2021, 1.4 out of 1,00,000 people are diagnosed with the disorder every year and the number is only expected to increase in the coming years. The rise in the medical cases of scleroderma is expected to aid the global scleroderma diagnostics and therapeutics market growth. Post Covid-19, research institutes have begun extensive work on novel products to stay better prepared for the future which is aided by the increasing investment and support from government agencies along with private market players. Along with this, there is a rising trend of adopting inorganic techniques like mergers & acquisitions between businesses to better reach the target audience and all of these reasons are expected to further the global market demand. One of the major global market growth drivers is the off-label drug use in case of approved symptomatic conditions like rheumatoid arthritis.

High cost associated with scleroderma diagnostic and treatment is likely to restrain the global market growth whereas a growing focus on the development of innovative methods is estimated to provide growth opportunities in the global market. Strict regulations for the approval of drugs and diagnostic devices for scleroderma may act as a challenge to the market growth.

The global scleroderma diagnostics and therapeutics market is categorized based on diagnostic test type, indication, drug class, and region. The diagnostic test type segment comprises blood tests, imaging techniques, skin biopsy, pulmonary function tests, and electrocardiogram & echocardiogram. Based on the indication, the global market is bifurcated into systemic scleroderma and localized scleroderma. The drug class segment is classified into prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase 5 inhibitors – PHA, immunosuppressors, analgesics, calcium channel blockers, and others.

North America is expected to dominate the global scleroderma diagnostics and therapeutics market owing to the recent development of immunosuppressants and excellent healthcare infrastructure. A higher diagnosis rate in the region coupled with high per capita income amongst the general population and more use of generics & biosimilars for off-label treatment of scleroderma will aid the regional growth.

Europe is expected to become the second most dominant regional market because of extensive R&D on scleroderma and government initiatives for generating mass awareness about the disease.

Asia-Pacific is showing signs of steady growth in the coming years because of the increasing population and increasing cases of scleroderma along with the opening of multiple treating facilities in the region.

Bayer AG; Boehringer Ingelheim International GmbH, arGentis Pharmaceuticals, LLC, Celgene Corp., Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd., Corbus Pharmaceuticals Holdings, Seattle Genetics, Inc., Kadmon Holdings, Inc., Emerald Health Pharmaceuticals, and Prometic Life Sciences, Inc. are some of the major players that are successfully operating in the global scleroderma diagnostics and therapeutics market.

Recent Developments:

• In March 2021, Roche received approval for Actemra®/RoActemra® (tocilizumab) subcutaneous injection from the US Food and Drug Administration (FDA) for decreasing the rate of drop in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a chronic condition with few treatment options. The FDA has approved Actemra/RoActemra as the first biologic medication for the treatment of the condition.

Browse the full “Scleroderma Diagnostics And Therapeutics Market By Diagnostic Test Type (Blood Tests, Imaging Techniques, Skin Biopsy, Pulmonary Function Tests, And Electrocardiogram & Echocardiogram), By Indication (Systemic Scleroderma And Localized Scleroderma), By Drug Class (Prostacyclin Analogues, Endothelin Receptor Antagonists, Phosphodiesterase 5 Inhibitors – PHA, Immunosuppressors, Analgesics, Calcium Channel Blockers, And Others), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/scleroderma-diagnostics-and-therapeutics-market

Global scleroderma diagnostics and therapeutics market is segmented as follows:

By Diagnostic Test Type

• Blood Tests
• Imaging Techniques
• Skin Biopsy
• Pulmonary Function Tests
• Electrocardiogram & Echocardiogram

By Indication

• Systemic Scleroderma
• Localized Scleroderma

By Drug Class

• Prostacyclin Analogues
• Endothelin Receptor Antagonists
• Phosphodiesterase 5 Inhibitors – PHA
• Immunosuppressors
• Analgesics
• Calcium Channel Blockers
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com